A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Efficacy and Tolerability of Oral BVT.115959, a Novel A2A Agonist, Versus Placebo in the Treatment of Diabetic Neuropathic Pain

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Efficacy and Tolerability of Oral BVT.115959, a Novel A2A Agonist, Versus Placebo in the Treatment of Diabetic Neuropathic Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2014

At a glance

  • Drugs BVT 115959 (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 07 Apr 2008 Primary endpoint not met
    • 07 Apr 2008 Results reported in a Biovitrum media release.
    • 15 Jan 2008 Status changed to completed, according to clinicaltrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top